Richard W. Joseph, MD

Articles by Richard W. Joseph, MD

Dr. Joseph on Molecular Signatures in mRCC

September 3rd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on the Combination of Atezolizumab and Bevacizumab in mRCC

ByRichard W. Joseph, MD

August 23rd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

ByRichard W. Joseph, MD

August 5th 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Selecting Frontline Therapy in mRCC

ByRichard W. Joseph, MD

August 2nd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the process of selecting frontline therapy in metastatic renal cell carcinoma (mRCC).